Reminder of the exercise of warrants of Series TO 1 B
The exercise period for the Series TO 1 B subscription warrants that were issued in connection with Calmark Sweden AB (publ)'s ("Calmark") spring/summer 2018 issue of units prior to listing is ongoing until June 13, 2019. Last day of trading of subscription warrants of Series TO 1 B is June 11, 2019. Holders of subscription warrants for Series TO 1 B are entitled, for each warrant, to subscribe for one new B share in the company at a price of SEK 5.40 per share. On full exercise of all Series TO 1 B subscription warrants, 3 000 000 B shares will be issued and Calmark will raise approximately MSEK 16.2 before issue costs.
Subscription of class B shares with the support of Series TO 1 B subscription warrants may take place until June 13, 2019, and this shall be done by simultaneous cash payment no later than 15.00 on 13 June 2019. Conversion of interim shares to B shares is expected to take place during week 28.
Note that the last day of trading of subscription warrants of Series TO 1 B at Spotlight Stock Market is June 11, 2019. Also note that subscription warrants of Series TO 1 B fall due without value if the holder does not actively subscribe for shares by June 13, 2019 or sell their subscription warrants by June 11, 2019 at the latest.
Teaser and application form are available on the websites of Calmark (www.calmark.se), Sedermera Fondkommission (www.sedermera.se) and Spotlight Stock Market (www.spotlightstockmarket.com).
Financial advisor
Sedermera Fondkommission is the financial advisor and issuing agent of Calmark in connection with the exercise period for the company’s Series TO 1 B subscription warrants.
For more information regarding the subscription of Series TO 1 B subscription warrants, please contact:
Sedermera Fondkommission
Telephone: +46 40-615 14 10
E-mail: info@sedermera.se
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 213 25 35
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analyzis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the first period of life, regardless of where in the world a baby is born. Read more about Calmark www.calmark.se/eng/home.
Tags: